CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0060 (clinicaltrials.gov NCT No: NCT01664897)
Title:A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory/Relapsed AML
Principal Investigator:Jorge Cortes
Treatment Agent:Erlotinib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if erlotinib can help to
control AML. The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Erlotinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Astellas Pharmaceuticals
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults